Testing effectiveness (Phase 2)UnknownNCT02946359What this trial is testingA+C in Metastatic Lung Adenocarcinoma CancerWho this might be right forLung Adenocarcinoma Metastatic Chinese PLA General Hospital 60
Early research (Phase 1)Active Not RecruitingNCT02609776What this trial is testingStudy of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung CancerWho this might be right forNon-Small-Cell Lung Cancer Janssen Research & Development, LLC 751
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06885840What this trial is testingStudy of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.Who this might be right forNon-Small Cell Lung Cancer Betta Pharmaceuticals Co., Ltd. 100
Testing effectiveness (Phase 2)Looking for participantsNCT06109558What this trial is testingThe Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLCWho this might be right forNon Small Cell Lung CancerRET Gene MutationMET Amplification+1 more Hunan Province Tumor Hospital 120
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06452433What this trial is testingGumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.Who this might be right forNon-small Cell Lung Cancer Cancer Institute and Hospital, Chinese Academy of Medical Sciences 91
Testing effectiveness (Phase 2)UnknownNCT05163249What this trial is testingOsimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLCWho this might be right forCarcinoma, Non-Small-Cell Lung Guangdong Association of Clinical Trials 44
Testing effectiveness (Phase 2)UnknownNCT02499614What this trial is testingCrizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)Who this might be right forCarcinoma, Non-Small-Cell Lung Fondazione Ricerca Traslazionale 80
Large-scale testing (Phase 3)Looking for participantsNCT06829459What this trial is testingEvaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIsWho this might be right forNon-Small Cell Lung Cancer Shanghai JMT-Bio Inc. 350
Testing effectiveness (Phase 2)Looking for participantsNCT06980532What this trial is testingGlumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal CancerWho this might be right forMetastatic Colorectal Cancer Liu Huang 42
Early research (Phase 1)Active Not RecruitingNCT03333343What this trial is testingStudy of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLCWho this might be right forEGFR-mutant Non-small Cell Lung Cancer Novartis Pharmaceuticals 105
Testing effectiveness (Phase 2)WithdrawnNCT03240393What this trial is testingStudy of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)Who this might be right forCarcinomaNon-Small-Cell Lung Cancer Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT02414139What this trial is testingStudy of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)Who this might be right forCarcinoma, Non-Small-Cell Lung Novartis Pharmaceuticals 373
Testing effectiveness (Phase 2)Looking for participantsNCT06947291What this trial is testingSafety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid TumorsWho this might be right forAdvanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 350
Testing effectiveness (Phase 2)Looking for participantsNCT05800340What this trial is testingNeoadjuvant Immunotherapy in Rare Mutations Localized NSCLCWho this might be right forNon-Small Cell Lung CancerRET Driver MutationBRAF V600 Mutation+3 more Guangdong Provincial People's Hospital 30
Testing effectiveness (Phase 2)Looking for participantsNCT07196644What this trial is testingAssess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab AdizutecanWho this might be right forSolid Tumors Harboring MET Amplification AbbVie 100
Testing effectiveness (Phase 2)Looking for participantsNCT06574347What this trial is testingVebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.Who this might be right forNon-Small-Cell Lung Cancer Avistone Biotechnology Co., Ltd. 120
Early research (Phase 1)Active Not RecruitingNCT03993873What this trial is testingStudy of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in METWho this might be right forAdvanced Solid TumorMetastatic Solid TumorsMET Gene Alterations Turning Point Therapeutics, Inc. 95
Testing effectiveness (Phase 2)Ended earlyNCT02132598What this trial is testingTrial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain MetastasesWho this might be right forNon Small Cell Lung Cancer (NSCLC)Metastases to the Brain Liza Villaruz, MD 5
Large-scale testing (Phase 3)Ended earlyNCT04816214What this trial is testingStudy Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line TherapyWho this might be right forCarcinoma, Non-Small-Cell Lung Novartis Pharmaceuticals 6
Testing effectiveness (Phase 2)Looking for participantsNCT04270591What this trial is testingAssessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung CancerWho this might be right forC-Met Exon 14 Mutation Haihe Biopharma Co., Ltd. 183